Hepatic applications of sonography include evaluation of the gallbladder and bile ducts, assessment of patients with suspected portal hypertension, and evaluation of focal and diffuse parenchymal liver disease. Ultrasound imaging (US) is generally a reliable and accurate method to diagnose a variety of hepatic abnormalities; however, in some cases there is a need to improve sonography's sensitivity and specificity, particularly for the detection and characterization of hepatic masses. Recent clinical experience has shown that the addition of a US contrast agent can enhance sonography's diagnostic capabilities including improving assessments of hepatic blood flow and the detection and characterization of hepatic neoplasms. One intravenously administered US contrast agent is now available in the United States, but its approved indication is limited to echocardiographic applications. Additional agents that have more diagnostic applications are likely to become available. Contrast-enhanced sonography may play a significant role in the diagnosis and management of patients with suspected hepatic abnormalities. This article describes two generic types of US contrast agents-vascular agents and tissue-specific agents-and includes a review of recent published reports on clinical applications of contrast-enhanced hepatic sonography.
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Hepatic applications of diagnostic medical sonography include evaluation of the gallbladder and bile ducts, assessment of patients with suspected portal hypertension (PHT), assessment of the transplanted organ recipient, and evaluation of focal and diffuse parenchymal liver disease. Sonography is considered a reliable and accurate means to diagnose a number of commonly encountered hepatic abnormalities, including gall stones and biliary obstruction. However, in some cases, there remains room for improvement in terms of sonography's sensitivity and specificity, particularly for the detection and characterization of hepatic neoplasms. When a hepatic ultrasound imaging (US) examination is equivocal or otherwise diagnostically inadequate, an alternative imaging study such as magnetic resonance imaging (MRI) or computed tomography (CT) is often required. Contrast is commonly included in CT and MRI examinations of the liver, which improves their sensitivity and specificity as well as overall diagnostic utility. However, recent clinical experience has shown that the addition of contrast to the US examination can have similar advantageous effects on its diagnostic potential. Ultrasound contrast agents have also been found to improve Doppler US assessment of blood flow to, in, and through the liver in both normal controls and patients with hepatic disease (Fig. 1 ). [1] [2] [3] [4] Several sonographic contrast agents are commercially available in the United States and elsewhere. Advances in US equipment technology and new scanning techniques have contributed to improving the effectiveness of contrast-enhanced sonography (CES). [5] [6] [7] [8] [9] [10] [11] CES may play a significant role in the diagnosis and management of patients with a variety of suspected hepatic abnormalities. Described below are two generic types of US contrast agents and a review of recent reports on various clinical uses of contrast-enhanced hepatic sonography.
Vascular Agents
Sonographic detection of blood flow is limited by factors including the depth and size of a vessel, attenuation properties of intervening tissue, and low velocity and/or low volume flow. Limitations on flow sensitivity and US's operator dependency are additional factors that may affect the acquisition of clinically relevant imaging data and overall diagnostic value of a Doppler US examination. When using Doppler modes, vascular (a.k.a. blood pool or intravenous) US contrast agents enhance the detection of blood flow signals by adding more and better acoustic scatterers into the bloodstream. The addition of contrast during an US examination improves the ability to assess blood flow in vessels that, without their use, are often difficult to evaluate, such as the abdominal vasculature and capillaries within organs (i.e., organ perfusion). Intravenous agents also improve gray-scale US visualization of blood flow, particularly when new technological advancements such as pulse inversion (or phase inversion) gray-scale harmonic imaging modes are employed. [6] [7] [8] [9] In addition to being able to enhance the detection of blood flow, desirable characteristics of an intravenous US contrast agent include being nontoxic, being injectable intravenously, having microbubbles that are small enough to pass through capillary beds, and being stable enough to provide multiple recirculations. Several agents that are available now or may be available in the near future appear to possess these traits. A typical blood pool US contrast agent is composed of tiny microbubbles (a.k.a. microspheres or microparticles) of air or other gaseous compounds that are no larger than red blood cells (≤ 7 µm in size). The microbubble shell is composed of proteins, biocompatible polymers, phospholipids, or other compounds depending on the specific agent. Intravenous administration of contrast is via a peripheral venous bolus injection, or contrast can be infused. Contrast microbubble stability within the blood permits multiple recirculations and increases the duration of enhancement, which is a particularly important characteristic for hepatic applications, where additional time may be required to scan the entire liver (in some cases, multiple times). However, the micro-bubbles cannot be so stable that they are difficult to be eliminated or metabolized by the body. After the contrast microbubbles rupture, the gas and shell by-products go into the blood solution and are no longer efficient at enhancing US signals. Typically, when ruptured, the microbubble's gas is exhaled via the lungs and its shell components are eliminated or excreted from the body by normal physiologic mechanisms.
Examples of vascular agents currently in clinical trials or awaiting U.S. Optison is a microsphere-based contrast medium that is approved by the FDA for echocardiographic applications (e.g., to improve left ventricular opacification and endocardial border definition). The microspheres of Optison range in size from 2 to 4 µm and are composed of a denatured human serum albumin shell containing octafluoropropane gas. Although approved only for cardiac applications, Optison has been shown to have the ability to improve US assessment of blood flow in a variety of noncardiac applications (Fig. 2 ). 6, 7, 11 Presently in the United States, no intravenous contrast agents have FDA approval for noncardiac applications.
Depending on the agent, dose, imaging technique, and other factors, vascular enhancement times after intravenous administration of contrast range from approximately 3 minutes to more than 15 minutes per bolus injection. Additional contrast usually can be administered if contrast enhancement diminishes before the acquisition of all relevant data. Intravenous infusion of contrast generally provides a longer duration of enhancement than does a bolus injection. 1, 12 In the future, the infusion of contrast may be the preferred method of delivery for many radiological US applications, including hepatic scanning. 
Tissue-Specific Agents
While conventional (i.e., noncontrast) sonography of the liver and other abdominal organs is relatively sensitive to detect changes that result from infarctions, tumor infiltration, or other abnormalities, US often provides diagnoses that are less specific in comparison to other imaging modalities such as CT and MRI. Tissue-specific US contrast agents (a.k.a. organspecific agents) have the potential to improve assessment of various organs, including the liver, by enhancing the detection of abnormalities as well as increasing the confidence of excluding disease. Recent reports (using both vascular agents and tissue-specific agents) have shown that US contrast agents also improve the sonographic characterization of hepatic neoplasms. 7, 11, [13] [14] [15] [16] [17] [18] [19] Tissue-specific agents are intravenously administered in a manner similar to that used with blood pool agents. In fact, these agents sometimes also enhance the detection of blood flow during their vascular or blood pool phase. Over time, the contrast microbubbles are removed from the bloodstream by various mechanisms such as phagocytosis by the reticuloendothelial system (RES) in the liver and spleen. In the delayed or parenchymal phase, these agents improve assessments of an organ's parenchyma. The presence of intact stationary contrast microbubbles changes the tissues' acoustic properties (e.g., attenuation, impedance, propagation speed). This affects the tissues' backscatter characteristics and results in a change in the echogenicity of the affected tissue. These changes may require from several minutes to several days to become apparent or reach maximum effectiveness (depending on the specific agent). By enhancing the difference in reflectivity between normal and abnormal portions of organs, organ-specific contrast agents improve the detectability of focal abnormalities such as liver metastases ( Fig. 3) .
Sonazoid™ (Amersham, Buckinghamshire, UK) is a RES-specific agent currently in clinical trials in several countries including Germany, England, and the United States. Sonazoid is a liver-tissue-specific agent that initially enhances blood flow detection (in its vascular phase), and, over several minutes' time, the Kupffer cells of the liver phagocytize the contrast microparticles where they remain, intact in the liver parenchyma. In the delayed phase (5 or more minutes postinjection), normal liver tissue becomes more echogenic (i.e., enhances) whereas areas that do not contain normal liver cells (e.g., metastatic tumors and many other neoplasms) do not enhance. The differentiation of areas with and without contrast is therefore improved, and liver tumors become easier to identify on the delayed scan sequence (Fig. 4 ). 20, 21 FIG. 3. Contrast-enhanced detection and delineation of hepatic lesions. In a patient with known hepatocellular carcinoma (HCC), precontrast imaging (A) demonstrates a heterogeneous liver texture with a suggestion of multiple tumors. After administration of Sonazoid (B), gray-scale harmonic imaging in the delayed phase (16 minutes postinjection) demonstrates increased echogenicity of normal liver parenchyma whereas areas without normal liver cells do not enhance (i.e., remain dark on the ultrasound image). Note that the attenuation of the ultrasound beam caused by the increased echogenicity of the contrast-enhanced tissue limits visualization of the deeper portions of the liver. In this case, contrast improved the conspicuity of a significant number of HCC metastases within the liver that were not appreciated precontrast. Tumors as small as 5 mm were clearly identified postcontrast (arrow).
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Levovist™ (Schering AG, Berlin, Germany) is primarily used as a blood pool agent but also has a short-lived delayed hepatic parenchymal (RES) phase. Levovist is not approved for use in the United States, but it is approved for use in other countries including the European Union nations, Australia, and Japan. A number of clinical studies using Levovist for contrastenhanced hepatic sonography have been reported. [1] [2] [3] [12] [13] [14] [15] 22 Many reports have described the use of various blood pool agents and their ability to enhance the detection or conspicuity of hepatic lesions and to rule out the presence of tumors ( Fig. 5 ). However, timing of contrast administration as it relates to US scanning is critical to adequately evaluate contrast-enhanced blood flow (in the macrovasculature and microvasculature) and determine flow characteristics in various phases using vascular agents. For hepatic applications, RES-specific agents offer potential advantages over vascular agents; delayed phase imaging can be performed as much as 15 minutes (perhaps more) after contrast administration, and the parenchymal phase provides additional data in terms of identifying differential uptake of contrast between normal and abnormal tissue. 20, 21 Contrast enhancement of liver tissue with one tissue-specific agent has been reported to last for up to 2.5 hours in an animal model. 20 In the future, tissue-specific agents may prove to be more practical for contrast-enhanced hepatic sonography.
Clinical Reports on Contrast-Enhanced Hepatic Sonography
A majority of reports describing the potential utility of contrast-enhanced hepatic sonography have focused on the detection and/or characterization of focal liver tumors. 3, 7, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] This abundance of reports on the use of contrast for this application is an indication of conventional US's current diagnostic limitations and of how clinically important contrast-enhanced hepatic sonography may be in the future. Other reports have described sonographically detectable alterations in blood flow transit time through the liver in patients with hepatic disease when compared to normal controls. 2, 3 This is an intriguing application of the modality that cannot be performed without the use of contrast agents. However, additional work still needs to be done to determine the ultimate clinical utility of this new diagnostic technique.
Currently, many patients with hepatic tumors who are first identified sonographically eventually require a CT or MRI examination to better determine the extent of disease as well as to more accurately characterize the tumors. This information is critical to the referring physician and allows them to properly manage their patient and identify the most appropriate course of treatment. In the future, when US contrast is more widely available, the need for these more expensive imaging modalities may decline. Many of the same diagnostic criteria currently used for contrastenhanced CT or MRI including evaluation of the degree, timing, and pattern of vascularity in and around hepatic tumors can also be applied to contrastenhanced sonography. 4 In fact, sonography, because of its ability to image dynamic events in real time, may prove to be better than CT or MRI in the evaluation of hemodynamics that occur in the various hepatic vascular phases (i.e., hepatic arterial and portal venous flow phases). Additionally, recent reports suggest that the timing of contrast uptake and washout (i.e., contrast kinetics) within a hepatic tumor as it compares to adjacent normal parenchyma may provide valuable additional diagnostic information that can improve the ability to sonographically characterize hepatic lesions (Fig. 6 ). 4, 11, 14, 16, 18, 19 This information is simply not obtainable without the use of a contrast agent. A multicenter trial reported by Needleman et al. 21 attempted to identify the potential benefits of using Sonazoid to enhance the detection of focal hepatic lesions. They reported that the number of CT or MRI verified lesions identified after contrast was statis-FIG. 5. Improved detection of intrahepatic vascularity. Baseline gray-scale harmonic imaging (A) suggests the presence of a poorly defined mass (between arrows) in the right lobe of the liver of a patient with cirrhosis. After injection of Definity (B), contrast-enhanced blood flow is seen in the intrahepatic portal veins and hepatic arteries and in vessels around the suspicious area (curved arrows). After a second aliquot injection (C), there is an overall increase in echogenicity throughout the liver as well as in the suspicious area (T) that is isoechoic to the surrounding hepatic tissue. This represented a regenerating nodule in the cirrhotic liver. tically significantly greater in comparison to precontrast studies. Another finding from this study was that the delineation of hepatic lesions improved on the postcontrast imaging scans; before contrast administration, 67% of lesions were well circumscribed, whereas 92% of lesions were well circumscribed after contrast administration. Contrast enhancement was observed to last for more than 15 minutes postinjection. This study demonstrates how contrast can aid in the detection of hepatic masses, which is an application that has extensive clinical implications. However, once a lesion is detected, the next step is to accurately characterize the lesion, and contrast-enhanced sonography also appears promising in this capacity. Plew et al. 13 used Levovist and color Doppler imaging (CDI) to prospectively evaluate 25 patients with known hepatic tumors ranging in size from 0.5 cm to 7.0 cm. There were 13 benign and 12 malignant lesions (4 hepatocellular carcinomas [HCCs] and 8 metastases). Vascular enhancement was achieved in 18 lesions, including all 12 malignant and 6 of the and an increase in echogenicity of the tumor (T). The relative hypervascularity of the tumor is indicated by its significant increase in echogenicity compared to the surrounding parenchyma during the early portal venous phase. Imaging in the parenchymal phase approximately 12 minutes after injection (C) demonstrates an increase in echogenicity of the normal hepatic tissue whereas the tumor (T), which does not have contrast uptake, remains hypoechoic. Note the lack of contrast in the vessels on the delayed scan. These multiphase findings were consistent with hepatocellular cancer, subsequently confirmed by magnetic resonance imaging. C B A benign tumors (4 focal nodular hyperplasias and 2 hemangiomas). They concluded that nonenhancing hepatic lesions may be benign, but that it was not possible to distinguish between metastases and hemangiomas if the pattern of vascular enhancement was peripheral.
In another study with Levovist, Strobel et al. 17 examined 105 hepatic tumors in 100 patients with pathology or additional imaging correlations. In this study, precontrast gray-scale and CDI as well as contrast-enhanced CDI were used to determine the ability to accurately diagnose the liver tumors. Correct baseline diagnoses were made in 33 of 105 (31%) cases, whereas the additional color flow information provided by contrast increased the number of correct diagnoses to 60 of 105 (57%).
Solbiati et al. 18 evaluated contrast kinetics in 36 cirrhotic patients with 51 focal hepatic tumors. SonoVue was used with gray-scale harmonic imaging. They found that imaging in the early arterial phase provided the best means to differentiate HCCs, with 83% of HCCs demonstrating marked homogeneous enhancement while regenerating or dysplastic nodules did not exhibit enhancement in this phase. In the portal phase, HCCs showed rapid washout of contrast whereas other lesions demonstrated an increase in echogenicity. Hemangiomas were characterized by their early nodular enhancement pattern with additional progressive enhancement over time (consistent with the typical appearance of hemangiomas on CT). The authors concluded that arterial phase imaging was critical for the differentiation of HCCs from other focal tumors in cirrhotic patients.
Cavernous hemangiomas are the most common benign solid neoplasms of the liver and are frequently detected during hepatic US studies. 23 The typical sonographic appearance of a hemangioma includes a rounded, homogeneously hyperechoic mass with welldefined margins. But not all hemangiomas have the "classic" US appearance nor can they all be accurately characterized sonographically. Often, patients require a contrast-enhanced CT or MRI for a more definitive diagnosis, particularly if there is suspicion of a malignancy. Several recent reports have suggested that contrast-enhanced hepatic sonography can improve the assessment of hemangiomas and allow a more accurate US diagnosis. 11, 14, 16 Weskott 14 reported using US contrast and interval delay gray-scale harmonic imaging (with several different delay times) in an attempt to identify the hemodynamic patterns most consistent with hemangiomas. Fifteen atypical (i.e., hypoechoic) hemangiomas ranging in size from 8 mm to 45 mm were evaluated before and after bolus administration of Levovist. Correlations were made with CT or MRI. All small hemangiomas demonstrated near complete enhancement, with three of the small tumors possessing a central nonenhanced area. The time interval for refill of lesions less than 2 cm in size was less than 4 seconds. Some larger lesions required up to 3 minutes to demonstrate enhancement, with a few larger masses demonstrating areas that did not enhance, which the author suggested was due to focal intratumoral thrombosis. Weskott concluded that most atypical hemangiomas show rapid refilling of contrast, suggesting that their blood supply is via arteries. Early and late vascular phase imaging provided a means to accurately characterize hemangiomas sonographically.
SonoVue was used in a study of atypical hemangiomas reported by Solbiati et al. 16 Seven atypical hemangiomas (1.5 to 6.5 cm in size) were evaluated with gray-scale harmonic imaging before and after bolus administration of contrast. Four lesions appeared hypoechoic or anechoic whereas the other three were isoechoic and "almost undistinguishable" on baseline US scans. Arterial, portal, and very late phase imaging was performed postcontrast injection. In the arterial phase, all lesions demonstrated only peripheral enhancement. In the portal phase, and even more so in the late phase, progressive centripetal filling lasting up to 5 to 7 minutes was observed in all lesions. Over time, the lesions became progressively more echogenic, which permitted a confident diagnosis. The authors concluded that multiphase sonography was necessary for accurate diagnosis of atypical hemangiomas and that this imaging technique has the potential to obviate the need for CT scans. They also suggested that contrast-enhanced multiphase imaging may be used to sonographically characterize other hepatic lesions.
A common hepatic application of US is for the evaluation of blood flow to, through, and from the liver, primarily in patients with suspected PHT. Most sonographic examinations for PHT include qualitative assessment of blood flow with color flow imaging to identify the presence and direction of flow in the splenic and superior mesenteric veins, as well as the main portal vein and the intrahepatic portal and hepatic veins. Quantification and characterization of portal venous hemodynamics is performed with pulsed Doppler and spectral analysis. When scanning patients with PHT, slow-moving portal venous flow can be difficult to detect. In these cases, an intravenous US contrast agent could be used to increase the reflectivity of portal vein blood, thus enhancing its detectability. The addition of a contrast agent during US evaluations of patients with PHT could also improve the detection of portal-systemic collaterals and evaluations of surgically created portosystemic shunts, as well as improving the confidence of diagnoses in cases of complete or partial portal vein thrombosis.
In a study of both normal volunteers and patients with cirrhosis, Sellars et al. 1 found that Doppler flow signals from the portal vein were enhanced in all cases after administration of Levovist. This study compared the duration of enhancement provided by a bolus administration to that of three different infusion rates (slow, medium, and fast). A bolus delivery provided the shortest duration of contrast enhancement, whereas the slow infusion technique provided the longest duration. Contrast enhancement persisted for 113 seconds (mean duration) after a bolus injection compared to as much as 569 seconds (mean duration) following a slow infusion.
Contrast has been found to be beneficial for evaluations of patients with transjugular intrahepatic portosystemic shunts (TIPS). 24 The TIPS is an angiographically placed shunt established between the intrahepatic portal system and a hepatic vein. The TIPS provides a direct conduit for blood arriving to the liver to be shunted back into the systemic circulation, thereby potentially reducing some of the serious sequelae of PHT such as esophageal varices and portal vein thrombosis. Often, patients with TIPS have underlying changes to their hepatic parenchyma (e.g., cirrhosis), which can result in increased US signal attenuation. This can present problems with sonographic visualization of the shunt lumen and evaluation of blood flow through the shunt as well as in vessels leading to and from the shunt. An intravenous contrast agent that can enhance the detectability of blood flow to and through the TIPS communication will generally facilitate these sometimes difficult and technically challenging examinations.
Intravenous US contrast has been used to evaluate flow in the hepatic artery in hepatic transplant recipients. Leutloff et al. 22 reported their findings of 21 patients (31 examinations) who received orthotopic liver transplants. After Levovist was administered, significantly better arterial flow signals were detected in the porta hepatis as well as in the right and left lobes of the liver. The authors concluded that the use of contrast-enhanced CDI significantly improved the detection of hepatic arterial flow in transplant recipients. This is a clinically important application of contrast-enhanced sonography because of the frequent use of US to evaluate organ recipients in the immediate postoperative period. Sonography, unlike some other imaging modalities, can be performed at the bedside of the critically ill patient. If the portable US exam is equivocal or suggests a problem with hepatic artery patency, an x-ray angiogram may be necessary to reach a definitive diagnosis. An US contrast agent used during the initial bedside sonogram could enhance the detection of hepatic artery flow and improve the interpreting physician's diagnostic confidence level, which could in turn reduce the number of unnecessary angiograms.
Finally, contrast may play a role in the diagnosis and treatment of patients who are going to have or have had hepatic chemotherapy, cryotherapy, radiofrequency, or other focal tumor ablation techniques. 4, 7, 25 Tissue-specific agents used during the planning stage of a US-guided ablation can provide a means to better define tumor size and delineate tumor margins, which would help ensure that the entire tumor is ablated while normal tissue is preserved. Patients who have had a tumor ablation procedure receive serial imaging examinations to check for residual viable tumor at the ablation site and to screen for tumor recurrence. Currently, CT and MRI are most commonly used for these serial studies. However, the use of CES for the follow-up examinations could increase (Fig. 7) . 26 If a radiofrequency ablation procedure is being considered, it is conceivable that if additional ablations are indicated by the contrast-enhanced US study, they could be performed (under US guidance) at the time of diagnosis, thus reducing the time between diagnosis and treatment and possibly improving the patient's outcome.
Conclusion
Sonography is commonly used to evaluate patients with a wide variety of suspected hepatic abnormalities.
Although a majority of conventional US examinations of the liver are diagnostically adequate, in some cases US provides less sensitive and/or specific diagnoses than other imaging modalities such as CT and MRI. Clinical experiences with both vascular and tissuespecific US contrast agents have shown that the addition of contrast improves sonography's diagnostic capabilities in hepatic applications. Vascular or blood pool agents improve the detection of blood flow in vessels throughout the body including the portal and hepatic veins and hepatic arteries, as well as flow in and around hepatic tumors. Tissue-specific agents have been found to enhance sonographic detection of liver tumors. A clinically important potential application of CES will be to improve the ability to sonographically detect and characterize hepatic tumors, and a significant amount of research is being performed in this area. Contrast may also be useful for planning and monitoring hepatic tumor ablation therapies. It is likely that advances in US technology such as gray-scale harmonic imaging will play a key role when using contrast in the future. Fig. 2 ). On the precontrast image, the lesion on the left (t) has a hypoechoic central area whereas the tumor on right (T) has a complex US appearance. Imaging after Optison administration, using a manual interval delay imaging technique, shows increased echogenicity resulting from the presence of contrast in the vascular spaces. Note the lack of contrast enhancement in the hypoechoic central necrotic area of the tumor on the left (t) that had previously been treated with chemotherapy. Contrast-enhanced sonography (CES) confirmed the complete lack of flow consistent with tumor necrosis. The lesion on right has increased contrast-enhanced blood flow with only small, scattered areas of necrosis (arrow). The presence of viable residual tumor tissue indicates a need for additional treatment of the tumor on the right. A computed tomography examination (C) without contrast (left) and with contrast (right) confirmed the CES findings (t = tumor on left of US images, T = tumor on right of US images). CES used in this capacity could aid in patient management following tumor ablation therapies.
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Levovist is currently available for clinical use in the European Union, Japan, Australia, and elsewhere, and many reports on the use of this agent are in the literature. Currently, only one intravenous US contrast agent is available in the United States (Optison), but its indication is limited to echocardiographic applications. Other contrast agents with broader diagnostic indications are likely to become available. Although recent reports are encouraging, additional clinical experience is necessary to determine the ultimate role of contrast-enhanced hepatic sonography.
